<DOC>
	<DOCNO>NCT00001030</DOCNO>
	<brief_summary>To compare efficacy safety clarithromycin alone versus rifabutin alone versus two drug combination prevention delay Mycobacterium avium Complex ( MAC ) bacteremia disseminate MAC disease . To compare parameter survival , toxicity , quality life among three treatment arm . To obtain information incidence clinical grade target gynecologic condition . Persons advance stage HIV consider particular risk develop disseminate MAC disease . The development effective regimen prevention disseminate MAC disease may substantial benefit alter morbidity possibly mortality associate disease treatment .</brief_summary>
	<brief_title>The Safety Effectiveness Clarithromycin Rifabutin Used Alone Combination Prevent Mycobacterium Avium Complex ( MAC ) Disseminated MAC Disease HIV-Infected Patients</brief_title>
	<detailed_description>Persons advance stage HIV consider particular risk develop disseminate MAC disease . The development effective regimen prevention disseminate MAC disease may substantial benefit alter morbidity possibly mortality associate disease treatment . Patients randomize receive clarithromycin alone , rifabutin alone , two drug combination daily . Patients evaluate every 4 week first 8 week every 8 week thereafter duration study . Patients follow 24 month . Per amendment , pharmacokinetic substudy conduct .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : PCP prophylaxis . Allowed : GMCSF GCSF . Erythropoietin . Therapies ( include antiretrovirals ) available expanded access treatment IND program . Other nonexperimental therapy available prescription . Antihistamines specifically exclude . Patients must : Evidence diagnosis HIV infection history AIDSdefining condition CDC criterion . CD4 count &lt; = 100 cells/mm3 within 90 day prior study entry . Two baseline blood sample culture negative MAC within 30 day study entry . No suspected disseminate MAC disease , opinion clinician . NOTE : Patients elevate GGT and/or triglyceride allow . NOTE : Patients may coenroll ACTG 081/981/181 , ACTG 175 , ACTG 204 , ACTG 193 , ACTG 241 , acceptable protocol . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known suspect tuberculous infection nontuberculous mycobacterial infection require chemotherapy chemoprophylaxis ( exception isoniazid prophylaxis alone ) . NOTE : Patients may enroll successfully complete tuberculosis ( TB ) treatment antiTB drug 6 month symptoms mycobacterial infection . Active TB . Known hypersensitivity study drug . Malabsorption define persistent diarrhea 8 stool per day &gt; 6 week . Concurrent Medication : Excluded : Frequent ( per month ) , repeat , continuous treatment course quinolones , erythromycin , spiramycin , azithromycin , clarithromycin , clindamycin . Concomitant terfenadine astemizole . Prior Medication : Excluded : Prophylaxis azithromycin , clarithromycin , rifabutin 4 month .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Rifabutin</keyword>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Clarithromycin</keyword>
</DOC>